CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Secretaria da Saúde (São Paulo - Estado). Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Biologist from Mackenzie University and PhD in Sciences from the Faculty of Medicine of the University of São Paulo - FMUSP, acting as a Scientific Researcher, level VI, in the area of Experimental Thoracic Surgery at the Institute of Medical Research Laboratories of the Hospital das Clínicas, Faculty of Medicine, University of Sao Paulo. Advisor professor of postgraduate programs in Experimental Pathophysiology (Master and Doctorate) and Thoracic and Cardiovascular Surgery (Doctorate) of FMUSP. Collaborating Professor, Department of Cardiopneumology, FMUSP. Lung transplant research lines: study of the effects of immunosuppressive agents on the mucociliary system of the airways; testing of new drugs to attenuate lung graft ischemia and reperfusion injury. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Lung transplantation is the only treatment option for patients with terminal lung diseases. However, mortality and morbidity resulting from bronchial, infectious and graft rejection complications remain high. Possible reasons for such a high incidence of infectious complications include an allograft that is continuously exposed to the environment, problems with bronchial anastomosis and d…
Lung transplantation (TxP) is the only alternative therapy for various diseases in advanced stadium of development, such as pulmonary emphysema, idiopathic pulmonary fibrosis and cystic fibrosis. However, several factors limit the success of TxP in later postoperative period, with a survival rate of just 53% and 30% after 5 and 10 years, respectively. Bronchiolitis obliterans (BO) is the …
(Only some records are available in English at this moment)
To complement the immunosuppressive regimens, at the time of lung transplantation or in the previous postoperative period, many centers are using as induction therapy the drug basiliximab which is an antibody antagonists of the Interleukin-2 receptor. It is known that the main cause of death in the first month after lung transplantation is infectious, coinciding with the same period of gr…
The ischemia and reperfusion (IR) is a complication that can raise the risk of death after lung transplantation, by activating the innate immune system to induce inflammation. This occurs when the supplemental oxygen in the lungs is interrupted (ischemia) followed by reperfusion period. During ischemia, oxygen supply is beneath metabolic needs, resulting in depletion of cellular ATP reser…
(Only some records are available in English at this moment)
| 7 / 7 | Completed research grants |
| 12 / 10 | Completed scholarships in Brazil |
| 19 / 17 | All research grants and scholarships |
| Associated processes | |